Effect of Rosuvastatin Therapy on HDL2 Level andAntiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD patients with hyperlipidemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007184

Enrollment

Unknown

Registered

2015-10-10

Start date

2015-11-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease (CHD).hyperlipidemia

Interventions

2:rosuvastatin

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with CAD undergoing quantitative coronary angiography; 2. Patients with hyperlipidemia: TG>1.6mmol/L and/or TC>4.6mmol/L, andthey didnt take antilipemic agents or steroid hormone at least three months before this trial; 3. Patients between the ages of 30 and75 years, the functions of liver or kidney are not severe.

Exclusion criteria

Exclusion criteria: 1. Acute Myocardial Infarction during the last half year; 2. Hypothyroidism; 3. Liver or Biliary Tract Diseases; 4. Renal Insufficiency or Kidney Failure; 5. Cerebrovascular Trauma; 6. Drug induce Hyperlipidemia, Familial Hypercholesterolemia; 7. Having a major trauma, operation with intestines andstomach within 3 months or the disease affecting drug absorbed; 8. Having Anaphylactic Reaction; 9. Mental Disorders anddrinking history; 10. Contraindication to rosuvastatin; 11. Pregnancy andlactation.

Design outcomes

Primary

Measure	Time frame
HDL (HDL2a, HDL2b, HDL3a, HDL3b, HDL3c);	—

Secondary

Measure	Time frame
total cholesterol;triglyceride;low density lipoprotein cholesterin;glutamic-pyruvic transaminase;glutamic oxalacetic transaminase;creatinine;Uric acid;	—

Countries

China

Contacts

Public ContactXukai Wang

wangxuk@163.com+86 13372700261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026